Emmanouil Papasavvas
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Single-cell Analysis of Glycomic and Proteomic Features of the HIV Reservoir
Open Date: 2022-08-01
Close Date: 2026-07-31
Grant: Close
Host Glycomic Modulation of HIV-associated Neuro-inflammation During Viral Suppression
Open Date: 2020-05-01
Close Date: 2026-03-31
Grant: Open
Glycomic Modulation of Gut Microbiome During HIV Infection
Open Date: 2019-12-24
Close Date: 2026-11-30
Grant: Close
HPV-Associated Cervical Lesion Grade Gene Expression and Cytokine Profile Correlates in HIV-1 Infection
Open Date: 2011-01-01
Close Date: 2012-01-01
Articles (14)
Lung-sparing radical pleurectomy with intraoperative photodynamic therapy (PDT) demonstrates remarkable survival for patients with pleural mesothelioma. Nevertheless, most patients treated with this multimodal approach will develop local tumor recurrence. An understanding of potential causes of treatment failure is central to developing mitigation strategies. Surgery importantly reduces disease burden but also produces tumor-promoting inflammation, as demonstrated through transcriptomic analysis of pleural mesothelioma specimens. Using preclinical models in the setting of combination therapy, we separated the benefit of surgical resection from its counterproductive effects on therapeutic outcome. Specifically, we evaluated mechanisms by which surgically induced inflammation can be therapy-limiting in a murine model of tumor incision (TI) introduced by a surgical cut across the tumor. In this TI model, we identified distinct TI-altered patterns in innate and adaptive inflammatory cells in murine mesothelioma tumors, and we studied changes in these patterns with the addition of PDT. TI introduction of an immunosuppressive environment is established via upregulation of PD-1/PD-L1 expression on tumor cells, T cells, and myeloid cells that is partially resolved by PDT. Immune dysfunction is further mitigated by the addition of PD-1 blockade, leading to curative potential in a process that requires Ly6G+ neutrophils and CD8+ T cells. Overall, these studies suggest that, without PDT, surgical modulation of immune cell trafficking and functionality leads to systemic immunosuppression. This immunosuppressive state potentially interferes with the generation of antitumor immunity by PDT. However, targeted inhibition of surgery-induced signaling in the PD-l/PD-L1 pathway counteracts surgery’s immunosuppressive outcomes to enhance PDT efficacy in the intraoperative setting. Significance: Surgery combined with PDT extends survival for patients with mesothelioma, but these patients are still at risk for tumor recurrence, in part due to the immunosuppressive effects of surgery. We find, in a mouse model, that combining surgery, PDT, and immune checkpoint blockade maximizes the efficacy of these therapies.
Year:
2025
Year:
2025
Reactivation of the latent viral reservoirs is crucial for a cure of HIV/AIDS. However, current latency reversing agents are inefficient, and the endogenous factors that have the potential to reactivate HIV in vivo remain poorly understood. To identify natural activators of latent HIV-1, we screened a comprehensive peptide/protein library derived from human hemofiltrate, representing the entire blood peptidome, using J-Lat cell lines harboring transcriptionally silent HIV-1 GFP reporter viruses. Fractions potently reactivating HIV-1 from latency contained human Retinol Binding Protein 4 (RBP4), the carrier of retinol (Vitamin A). We found that retinol-bound holo-RBP4 but not retinol-free apo-RBP4 strongly reactivates HIV-1 in a variety of latently infected T cell lines. Functional analyses indicate that this reactivation involves activation of the canonical NF-κB pathway and is strengthened by JAK/STAT5 and JNK signalling but does not require retinoic acid production. High levels of RBP4 were detected in plasma from both healthy individuals and people living with HIV-1. Physiological concentrations of RBP4 induced significant viral reactivation in latently infected cells from individuals on long-term antiretroviral therapy with undetectable viral loads. As a potent natural HIV-1 latency-reversing agent, RBP4 offers a novel approach to activating the latent reservoirs and bringing us closer to a cure.
Year:
2025
Year:
2025
PD-1 blockade is minimally effective in AB12 and AE17O mouse mesothelioma tumors before or after TI. A, In subcutaneous AB12 mouse mesothelioma tumors, TI significantly decreased the median tumor growth time to 400 mm 3 from 7 days compared with 9 days in untreated TC ( P = 0.025). For TC, n = 17 mice and for TI, n = 11 mice. B, The addition of αPD-1 (TC/αPD-1, dotted black line) to TC did not significantly change tumor response ( P = 0.27). In the TC/αPD-1 group, one mouse was censored because of tumor ulceration and subsequent early euthanasia. For TC/αPD-1, n = 12 mice. C, The addition of αPD-1 to TI led to significantly better outcomes with a slight delay in the median tumor growth time to 400 mm 3 (7 days for TI and 11 days for TI/αPD-1; P = 0.028) For TI/αPD-1, n = 11 mice. D, In AE17O tumors, TI produced a modest insignificant increase in tumor growth compared with TC ( P = 0.057 with a median of 13 days for TI vs. 14 days for TC). For TC, n = 10 mice and for TI, n = 11 mice. E, Adding αPD-1 in AE17O TC mice delayed the median time for tumor growth to 400 mm 3 by 1 week from 14 days in TC mice to 21 days after TC/αPD-1 ( P n = 12 mice. F, The addition of αPD-1 to TI also led to significantly better outcomes with a median time to 400 mm 3 increasing from 13 days after TI to 17 days for TI/αPD-1 ( P n = 12 mice. G and H, In AB12 tumors, flow cytometry of TC and TI tumors found a significant drop in PD-1 levels 2 days after a single αPD-1 dose for ( G ) CD4 + T cells and ( H ) CD8 + T cells. For TC n = 11 tumors, for TC/αPD-1 n = 11 tumors, for TI n = 14 tumors, and for TI/αPD-1 n = 10 tumors. Tumor responses (time to 400 mm 3 ) are compared using a log-rank (Mantel–Cox) test; comparisons of continuous outcomes used a Mann–Whitney test.
Year:
2025
PD-1 blockade significantly decreases tumor growth rates in combination with TI/PDT. αPD-1 initiated 1 hour after PDT and continuing 2× weekly for 3 weeks did not significantly alter tumor growth rates. A, In AB12 mice, more than 50% of both PDT alone ( n = 14) and PDT/aPD-1 ( n = 12) had median survival (time to 400 mm 3 ) greater than 90 days, and no differences between groups were detected ( P = 0.56). B, In AE17O mice, median survivals of 33.5 days for PDT ( n = 34) and 40 days for PDT/αPD-1 ( n = 12) were similar ( P = 0.79). C, In AB12 tumor–bearing mice that received TI prior to PDT, αPD-1 significantly decreased the rate of tumor regrowth ( P = 0.005), with a median survival >90 days for TI/PDT/αPD-1 ( n = 13) and 24-day median survival in TI/PDT ( n = 16). TI/PDT/αPD-1 isotype control ( n = 13) was also significantly different from TI/PDT/αPD-1 ( P = 0.025) and similar to TI/PDT ( P = 0.87). D, In AE17O tumor–bearing mice that received TI prior to PDT, αPD-1 also significantly decreased the rate of tumor regrowth ( P = 0.025), with a median survival of 20.5 days for TI/PDT ( n = 18) and 26 days for TI/PDT/αPD-1 ( n = 20). In all tumor responses, vertical dashes indicate animals that were censored due to tumor ulceration or metastasis. Groups treated with an isotype for αPD-1 are plotted in pale orange. Tumor responses were compared using log-rank (Mantel–Cox) tests.
Year:
2025
PDT decreases PD-L1 expression and significantly reduces tumor growth after TI. TI/PDT-treated mice had significantly longer tumor growth times (to 400 mm 3 ) than TI mice for AB12 ( P A ) and AE17O ( P B ), with medians of 7 days for TI vs. 24 days for TI/PDT for AB12 and 13 days for TI vs. 20.5 days for TI/PDT for AE17O. In AB12 mice, n = 11 for TI and n = 16 for TI/PDT. In AE17O mice, n = 11 for TI and n = 18 for TI/PDT. C, CD11b + Ly6G + cells were significantly increased after TI/PDT ( n = 6) compared with TI ( n = 8) in AB12 tumors ( P P = 0.005). D, Tumors treated with PDT ( n = 6) similarly had increased Ly6G + cells ( P = 0.002) and decreased PD-L1 expression ( P = 0.005) compared with TCs ( n = 7). E, PDT after TI significantly decreased the proportion of Ly6G − cells ( P P = 0.008). F, The proportion of CD11b + Ly6G − cells as a subset of CD45 + immune cells decreased significantly after PDT ( P = 0.001), and their PD-L1 levels were lower on average but not significantly so ( P = 0.073). G, For CD45 − cells, TI/PDT led to a significant drop in the percentage of viable CD45 − cells ( P P = 0.30). H, PDT of CD45 − cells also significantly decreased viability ( P = 0.001), but no significant differences in PD-L1 expression of these cells were observed ( P = 0.29). Representative gates of viable CD45 − cells are shown below for each condition. I, Viable CD45 − cells after TI/PDT had significantly higher levels of PD-L1 than CD45 − cells after PDT alone ( P = 0.004). Tumor responses (growth to 400 mm 3 ) were compared using log-rank (Mantel–Cox) tests, and all other comparisons were made using a Mann–Whitney test. FSC-A, forward scatter area; SSC-A, side scatter area.
Year:
2025
TI upregulates PD-L1 expression on AB12 intratumoral myeloid cells. A, In AB12 tumors, all CD45 − cells, a combination of tumor and stromal cells, were significantly increased in PD-L1 expression 24 hours after TI compared with TC ( P = 0.014). B, For all CD45 + immune cells, PD-L1 levels slightly increased 24 hours after TI compared with TC ( P = 0.054). C, The percentage of intratumoral CD11b + Ly6G + cells (as % of all CD45 + cells) was increased by TI ( P = 0.014); however, changes in the levels of PD-L1 on these cells were not detected. D, The percentage of CD11b + Ly6G − myeloid cells was not significantly changed 24 hours after TI; however, TI tumors had significantly higher PD-L1 expression in this myeloid cell population ( P = 0.021). For all 24-hour data, n = 7 tumors for TC and 8 tumors for TI. E, After 5 days, the numbers of CD11b + Ly6G + cells were about 30% of all CD45 + cells for both TC and TI tumors. At this time point, PD-L1 expression remained unchanged. However, CD62L expression (L-selectin) significantly increased for mice that received TI ( P = 0.007). F, For CD11b + Ly6G − cells, no differences were observed in population numbers or PD-L1 levels. For all 5-day data, n = 8 for TC and n = 8 for TI. Comparisons were made using a Mann–Whitney test. FMO, fluorscence minus one.
Year:
2025
Lung-sparing radical pleurectomy with intraoperative photodynamic therapy (PDT) demonstrates remarkable survival for patients with pleural mesothelioma. Nevertheless, most patients treated with this multimodal approach will develop local tumor recurrence. An understanding of potential causes of treatment failure is central to developing mitigation strategies. Surgery importantly reduces disease burden but also produces tumor-promoting inflammation, as demonstrated through transcriptomic analysis of pleural mesothelioma specimens. Using preclinical models in the setting of combination therapy, we separated the benefit of surgical resection from its counterproductive effects on therapeutic outcome. Specifically, we evaluated mechanisms by which surgically induced inflammation can be therapy-limiting in a murine model of tumor incision (TI) introduced by a surgical cut across the tumor. In this TI model, we identified distinct TI-altered patterns in innate and adaptive inflammatory cells in murine mesothelioma tumors, and we studied changes in these patterns with the addition of PDT. TI introduction of an immunosuppressive environment is established via upregulation of PD-1/PD-L1 expression on tumor cells, T cells, and myeloid cells that is partially resolved by PDT. Immune dysfunction is further mitigated by the addition of PD-1 blockade, leading to curative potential in a process that requires Ly6G + neutrophils and CD8 + T cells. Overall, these studies suggest that, without PDT, surgical modulation of immune cell trafficking and functionality leads to systemic immunosuppression. This immunosuppressive state potentially interferes with the generation of antitumor immunity by PDT. However, targeted inhibition of surgery-induced signaling in the PD-l/PD-L1 pathway counteracts surgery’s immunosuppressive outcomes to enhance PDT efficacy in the intraoperative setting. Significance: Surgery combined with PDT extends survival for patients with mesothelioma, but these patients are still at risk for tumor recurrence, in part due to the immunosuppressive effects of surgery. We find, in a mouse model, that combining surgery, PDT, and immune checkpoint blockade maximizes the efficacy of these therapies.
Year:
2025
Mesothelioma surgery in humans and mice alters immune pathways. A, RNA-seq analysis was performed on tumor tissue isolated over the time course of surgery from 31 patients with PM. Volcano plot of significant gene expression changes associated with time of sample collection showing strength of correlation with time (Spearman rho) and significance of association based on DESeq2 algorithm. FDR P value and/or correlation coefficients highlighted. dn, downregulated; ns, nonsignificant; up, upregulated. B, Analysis of FDR Z -score >2 are shown. The color scale intensity, with red showing activated pathways and blue showing inhibited pathways, indicates significance of enrichment ( P value). Numbers of differentially expressed genes in each pathway are indicated to the right of each bar. C, Heatmap showing log 2 gene expression versus average across tumor specimens for members of the IL-6 and IL-1 families with specimens sorted by the time from initiation of surgery (green bar at the top). Specimens from the same individual patients (uniquely shaped and color-coded) are marked at the time of collection. IL-6 and IL-1 pathways both show increased activity as surgery progresses. D, In the AB12 mouse mesothelioma TI model, IL-1Ra protein levels are higher at 4 hours after TI ( n = 7) compared with samples of untreated TC ( n = 6, Mann–Whitney test P = 0.001).
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Collaborators (14)
Gwendolyn Cramer
The Wistar Institute
Kevin Escandón
Researchers, Research Professional 5
University of Minnesota
Sandy Widura
The Wistar Institute
Jesper Gunst
VIP, Associate Professor
Aarhus University
Ole Søgaard
Professor
Aarhus University
John Frater
University of Oxford
Andrew Kossenkov
Assistant Professor
The Wistar Institute
Sunil Singhal
University of Pennsylvania
Konstantin MJ Sparrer
Ulm University
Theresa M. Busch
University of Pennsylvania
Steven Albelda
Professor
University of Pennsylvania
Christian Brander
ICREA Senior Research Professor
IrsiCaixa
Mary E. Putt
Professor
University of Pennsylvania
Amit Bar-Or
Professor
University of Pennsylvania
Make your next move.
Prepare your application
Review drafts before you send them.